Literature DB >> 29247283

Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.

Ana M Denis-Bacelar1,2, Sarah J Chittenden3, David P Dearnaley4, Antigoni Divoli3, Joe M O'Sullivan5, V Ralph McCready6, Bernadette Johnson4, Yong Du7, Glenn D Flux3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29247283     DOI： 10.1007/s00259-017-3902-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  Single high dose versus repeated bone-targeted radionuclide therapy.

Authors:  K Liepe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-31       Impact factor: 9.236

2.  A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

Authors:  J M O'Sullivan; A R Norman; V R McCready; G Flux; F M Buffa; B Johnson; J Coffey; G Cook; J Treleaven; A Horwich; R A Huddart; C C Parker; D P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

3.  Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.

Authors:  Hans-Jürgen Biersack; Holger Palmedo; Andrej Andris; Stefan Rogenhofer; Furn F Knapp; Stefan Guhlke; Samer Ezziddin; Jan Bucerius; Dirk von Mallek
Journal:  J Nucl Med       Date:  2011-10-05       Impact factor: 10.057

4.  Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Authors:  Scott T Tagawa; Matthew I Milowsky; Michael Morris; Shankar Vallabhajosula; Paul Christos; Naveed H Akhtar; Joseph Osborne; Stanley J Goldsmith; Steve Larson; Neeta Pandit Taskar; Howard I Scher; Neil H Bander; David M Nanus
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

5.  A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.

Authors:  Francesca M Buffa; Glenn D Flux; Matt J Guy; Joe M O'Sullivan; Victor R McCready; Sarah J Chittenden; David P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-22       Impact factor: 9.236

6.  Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

Authors:  Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan Slovin; William K Kelly; Dana Rathkopf; Gretchen A Gignac; David Solit; Lawrence Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph O'Donoghue; Steven Larson; Howard I Scher
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

Review 7.  Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.

Authors:  Ronak Saluja; Patrick Cheung; Katherine Zukotynski; Urban Emmenegger
Journal:  Urol Oncol       Date:  2016-03-19       Impact factor: 3.498

Review 8.  Palliative radiotherapy trials for bone metastases: a systematic review.

Authors:  Edward Chow; Kristin Harris; Grace Fan; May Tsao; Wai M Sze
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

9.  Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.

Authors:  Shi-Ming Tu; Paul Mathew; Franklin C Wong; Donnah Jones; Marcella M Johnson; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.

Authors:  Ana M Denis-Bacelar; Sarah J Chittenden; David P Dearnaley; Antigoni Divoli; Joe M O'Sullivan; V Ralph McCready; Bernadette Johnson; Yong Du; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-21       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.